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a  b  s  t  r  a  c  t
Aim: To analyze the literature data about lung oligometastatic patients who underwent SBRT
with regard to doses, fractionation, outcomes, response assessment and prognostic factors,
trying to define “the right patient” for the local treatment.
Background: “Oligometastatic disease” is defined as a state in which metastases are limited
in  number and site and characterized by unusual cancer biology and behavior. In this setting
local therapy could have a potential curative role. Recently, technological advances in Radi-
ation Oncology permitted the introduction of Stereotactic Body Radiation Therapy (SBRT), a
novel treatment modality that delivers ablative dose of radiation to the extra-cranial sites
with  high precision using single or a small number of fractions.
Materials and methods: We  performed a literature search using Medical Subject Heading terms
“stereotactic body radiation therapy” and “lung metastases”, considering a period of 10
years.
Results: Many non-randomized studies have shown that SBRT for lung oligometastases is
safe and effective, with local control rates of about 80%. To date SBRT represents an alter-
native and competitive option in patients with lung oligometastatic disease who refuse
surgical treatment or unsuitable for surgery. Based on published studies, SBRT might have
major benefit for a patient with breast histology, disease-free interval ≥12 months, control
of  the primary tumor, small lesions, limited number of lesions and higher radiation dose
delivered.ignedConclusions: Well-desdate, the discussion with
patients’ selection in the 
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.  SBRT  for  lung  metastases:  state  of  the  art
iterature data suggested the existence of “oligometastatic
isease” as a state in which metastases are limited in num-
er and site. Firstly in 1995, Hellman and Weichselbaum1
escribed this state characterized by unusual cancer biol-
gy and behavior. In relation to different clinical and
iological factors several authors stratified oligometastatic
atients in three subgroups in which various therapeutic
pproaches can be used.1–3 The first one includes de novo
ligometastatic patients who initially present with limited
etastases; the other one includes induced oligometastatic
atients who present with limited metastases as result
f systemic therapy; and the third one includes recurrent
ligometastatic patients who  present with limited metas-
ases as subsequently developed after treatment of initial
oco-regional disease. In this matter, the emerging data
re that local therapy could have a potential curative
ole.
The lung is the main site of metastatic disease from
he most solid tumors. Surgical resection has been recom-
ended in carefully selected patients.4 Anyway, there are no
rospective randomized controlled trials evaluating the role
f surgery in the management of these patients. However, the
ve-year survival rates are satisfactory, 30–65% in different
tudies.4–6
Recently, the technologies improvement changed the role
f Radiation Therapy from palliative to curative treatment
or lung oligometastatic patients. Stereotactic Body Radiothe-
apy (SBRT) allowed precise delivery of high radiation dose,
efined as “ablative dose”, with maximum sparing of nor-
al  tissue. To date, several papers have published on SBRT
bove all in stage I non-small-cell lung cancer7,8 and more
ecently also in lung oligometastatic patients. Heterogeneous
etrospective and few phase I–II prospective studies were pub-
ished with patients with different solid tumors, various sites
f metastatic disease (above all lung and liver) and different
otal dose and schedule. In some series the local control rate
s more  than 90%. Rusthoven et al. treated 63 lung lesions
nd reported local control rate of 96% at 2 years.9 In our pre-
ious report 2-year local control rate was 89% in 118 lung
esions.10 Based on these encouraging data, SBRT represents
 valid alternative local therapy in patients unsuitable for
urgery.
The big ongoing question is if and what a lot the best local
pproach might affect survival. Besides, the identification of
atients with true oligometastatic disease is not too easy; so,
nother important issue is what kind of patient can have a
ajor benefit from SBRT.
In this review we  analyzed the literature data about lung
ligometastatic patients who underwent SBRT. We  considered
he following points: prescribed total dose, employed fraction-
tion, clinical outcomes, treatment response and prognostic
actors. Besides we tried to identify “the right patient” for the
roper local treatment. We performed a literature search using
edical Subject Heading terms “stereotactic body radiation
herapy” and “lung metastases”, considering a period of 10
ears.therapy 2 0 ( 2 0 1 5 ) 446–453 447
2.  SBRT:  generality  and  radiobiological
advantages
The American Society of Radiation Oncology (ASTRO) defines
SBRT as external beam radiotherapy used to deliver a high
therapeutic dose of radiation, very precisely, to an extracra-
nial target within the body. The features of this technique are:
the use of a limited number of fractions (up to 5), high tar-
geting accuracy, rapid dose fall-off gradients and maximum
normal tissue sparing.11 The radiobiological advantages of
SBRT are the greater potential cell kill and the engaging of
sphingomyelin-based endothelial mechanism of tumor con-
trol related to the high dose per fraction. In advance, the
use of a limited number of fractions can lead to a poten-
tial reduction of the deleterious effect of tumor proliferation
that may occur during a longer course of radiotherapy. Vari-
ous dose-fractionation models have been proposed to predict
the effectiveness of radiotherapy doses and fractionation regi-
mens. The most widely used is the linear quadratic model,
which models cell kill from both double-stranded and poten-
tially repairable single-stranded DNA breaks. However, it
overestimates cell kill at high doses per fraction (e.g., the doses
used in SBRT), because there is proportionally more  lethal
damage to DNA and less sublethal damage.12 The general-
ized linear quadratic model has been suggested to incorporate
the conversion of sublethal to lethal DNA damage at high
doses per fraction more  accurately. Another model, the uni-
versal survival curve, incorporates both the linear quadratic
and multi-target models and can thus predict cell kill at
both high and low doses per fraction.13 Ablative radiothe-
rapy doses (i.e., those that destroy all living tissue in an
area) need to have a higher biologically effective dose (BED)
than do most conventionally fractionated regimens. BED is a
measure of the effectiveness of different dose fractionation
regimens, to allow comparison of different doses or doses
per fraction. No definition of the doses needed for ablative
radiotherapy is universally accepted. Multiple fractionation
schemes have been employed, ranging from 24 to 60 Gy in one
to five fractions. Anyway, regimens resulting in a biologically
effective dose larger than 100 Gy (˛/  ̌ = 10 Gy) would be deemed
ablative.14 More recently, some reports identified an active
role of radiotherapy in an immune-mediated mechanism. This
mechanism, defined as abscopal effect, is a response in non-
irradiated metastases and seems to be enhanced by the asso-
ciation of systemic immune modulators. The first preclinical
experiences suggested that fractionated radiotherapy would
better induce this interesting mechanism. Only preliminary
data have been published on abscopal effects after hypofrac-
tionated radiotherapy, but further evidences are needed.15,16
However, this effect might become particularly relevant in the
treatment of oligometastatic disease where the potentiating
of an immune response could be particularly efficacious.
3.  Technical  requirements  for  SBRTSBRT process requires a coordinated team effort between
the radiation oncologist, the medical physicist, the medical
d rad448  reports of practical oncology an
dosimetrist, and the radiation therapist. Protocols for Qual-
ity Assurance (QA) should be implemented to monitor and
assure proper functioning of the SBRT external beam delivery
unit, the image  guidance system as well as all other imag-
ing devices used for SBRT and the image-based 3D and/or
intensity-modulated treatment planning system.11
Because of the high radiation doses delivered, SBRT
requires very high confidence in target localization to limit the
amount of damage to surrounding normal tissues. Because of
the complex target motion of extracranial structures, however,
the treating physician must be able to take into account and
manage daily setup variability and intrafraction motion in a
way that allows for highly targeted therapy. This also requires
modern delivery systems with the ability to shape the pre-
scription isodose with a high degree of conformality. During
the CT simulation process, immobilization is necessary. There
are multiple reproducible systems that provide the necessary
immobilization—many of which are institution specific—such
as body frames, vacuum molds, abdominal compression
techniques, and thermoplastic devices. Such immobilization
strategies limit the effects of respiratory motion by restricting
chest wall rise and diaphragmatic excursion using an abdom-
inal pressure pillow. Alternatively, respiratory gating can be
used to track the patient’s range of motion throughout respi-
ration and deliver treatment only during the chosen phase of
the respiratory cycle.17 Given potential changes in the inter-
nal location of mobile tumors relative to external frames,
frame-based methods are generally supplemented with some
form of pretreatment image  guidance to confirm proper tumor
relocalization. Frameless stereotactic uses the fiducials that
are registered immediately before or during the targeting
procedure.11 In the management of lung and liver tumors,
four-dimensional CT scans or fluoroscopic motion studies are
conducted to provide accurate planning target volume (PTV)
measurements. For tumors with avidity for positron emission
tomography (PET), FDG-PET imaging is often performed with
the patient in a body mold to improve the accuracy of delin-
eating the tumor. Daily treatment image  guidance is essential
to ensure proper localization, reduce setup variability, and
ensure that there is not a geographic miss for each fraction.
Most commonly, this involves kilovoltage or megavoltage CT
guidance for the delivery of each fraction. Cone beam CT refers
to the incorporation of the imaging system into the linear
accelerator. A CT machine on rails takes advantage of a shared
tabletop for both CT imaging and a linear accelerator. All major
manufacturers of linear accelerators currently produce deliv-
ery systems incorporating CT guidance. A variety of other
systems with shared principles but different methods and
technologies are in use for SBRT as well, including the Novalis
BrainLAB system, TomoTherapy system, and Accuracy, Inc.,
CyberKnife system. The goal of dependable and reproducible
immobilization, motion management, and image  guidance
is to restrict necessary PTV margins yet ensure the desired
coverage of the CTV. There is no consensus on required PTV
margins, which are typically institution specific and depend
on an understanding of interfractional and intrafractional
variability for a given delivery system and disease site. Treat-
ment planning usually involves three-dimensional conformal
radiotherapy (3DCRT) with multiple beam arrangement, often
non-coplanar, or intensity-modulated radiotherapy (IMRT) toiotherapy 2 0 ( 2 0 1 5 ) 446–453
produce distributions with a very rapid fall-off. For all tech-
niques, the goal is to limit the volume of normal tissue
receiving the prescription dose.17
4.  Outcome  evaluation  in  relation  to  total
dose  and  fractionation
4.1.  Single  fraction
From 2004 to 2014 six retrospective studies have been pub-
lished on SBRT delivered in single fraction, three of them were
phase I–II prospective studies (Table 1).
Wulf et al. published their results related to patients
with oligometastatic disease. Twenty-five out of 51 metastatic
lesions were small peripheral lesions treated with single frac-
tion of 26 Gy, the other patients received a total dose of 30 Gy or
36 Gy/3 fractions. Mean clinical target volume (CTV) was 32 cc
(range 1–155). At a median follow-up of 9 months (range 2–37),
no local failure was observed in the single-dose group and
5/51 (10%) local recurrence/progression was seen in patients
who underwent three-fractions SBRT. The authors showed a
relationship between a single fraction compared with three
fractions. The 1-year actuarial local control rate for the 51
metastases was 80%.18 Fritz et al. reviewed data from 58
patients, 25 with pulmonary metastases (31 lesions) and 33
with early stage lung cancer. Lung metastases had a median
CTV of 6 cc (range 2.8–55.8) and the prescribed dose to isocen-
ter was 30 Gy in single fraction. After a median follow-up of
22 months (range 6.8–63), the local control rate of metastatic
lesions was 87%.19 Hof and colleagues analyzed data from 61
patients with 71 pulmonary metastases. Most of patients had
primary lung tumor and initially a single metastasis (67.2%),
with median CTV of 10 cc (range 1–53). The total prescribed
dose was 24–26 Gy in the majority of patients. After a median
follow-up period of 14 months the actuarial overall survival
at 1, 2, 3 years was 78.4%, 65.1%, and 47.8% respectively. The
authors evidenced a better local tumor control in patients with
smaller tumor volumes, solitary metastases (not developing
during the follow-up) and no primary colorectal cancer.20 More
recently, Ricardi et al. published our series of selected patients
with 1–3 lung lesions, maximum diameter of 5 cm,  ECOG 0–1,
absent or controlled extra-thoracic disease and an adequate
pulmonary function. Most of patients received a total dose of
26 Gy in single fraction or 45 Gy in 3 fractions. Median CTV
was 3.3 cc (range 0.2–19). They achieved 2-year local control
rate and Overall Survival of 89% and 66.5% respectively with
median follow-up of 20.4 months (range 3–77.4). Data analysis
confirmed smaller CTV (<3.3 cc) and single lesion as favor-
able prognostic factors for survival. No significant differences
were observed between single fraction and hypofractionated
group.21 An update of this series of patients homogeneously
selected and treated with single dose SBRT was published
by the same Institution on February 2014. After a median
follow-up time of 24 months, 1–2 years actuarial LC rates
were respectively 93.4% and 88.1%, while OS rates at 1 and
2 years were 85.1% and 70.5%, respectively. On multivariate
analysis, a disease-free interval longer than 24 months was
close to significance for a benefit in Cancer-Specific Survival.22
Osti et al. analyzed data from selected patients with 1–5 lung
reports of practical oncology and radiotherapy 2 0 ( 2 0 1 5 ) 446–453 449







Primary site Dose LC Toxicity








Fritz et al. 2006 25 31 All (mostly lung or
rectal tumor)




Hof et al. 2007 61 71 All (mostly from
lung cancer)










2-year LC 89% G3 (pneumonitis)
1.6%
G2 3.3%
















































Filippi et al. 2014 67 90 All (mostly
rectal tumo
etastases, maximum tumor diameter smaller than 50 mm,
ontrolled extra-thoracic disease with a limit of 2 sites, ade-
uate pulmonary function and ECOG performance status of
–1. After a median follow-up time of 15 months (range, 3–45
onths), local control rates at 1 and 2 years were 89.1% and
2.1% and overall survival rates were 76.4% and 31.2%. The
uthors showed a trend toward better local tumor control for
maller tumor volumes (<10 cc) and a statistically significantly
mprovement of LC rate for metastases from NSCLC, colon,
nd breast cancer than for other tumors like melanoma, renal
ell carcinoma, and sarcoma (radioresistant histologies).23
.2.  Hypofractionated  stereotactic  radiotherapy
ifteen studies on hypofractionated stereotactic radiotherapy
ere selected, as shown in Table 2 (patients with pulmonary
nd other sites of metastases) and Table 3 (selected patients
ith only lung metastases).
.2.1.  SBRT  for  different  lesion  sites
ersall et al. published data from 58 patients with primary
nd metastatic renal cell carcinoma. They treated 162 lesions,
ost of them were pulmonary metastases (72.4%). Most com-
on  prescribed dose was 30/40 Gy in 3 fractions, varied from
0 Gy per 4–5 fractions to 15 Gy per 3 fractions related to diam-
ter of the lesion. Total regression of treated lesions (30%)
as observed mainly for small lung metastases with mean
TV between 28.2 cc and 53.5 cc; no change or partial regres-
ion was recorded for lesions with mean CTV between 67.1 cc
nd 113.7 cc. Local control rate of 90% was observed with a
edian follow-up time of 37 months (range 7–80 months).24 A
imilar study was published by Svedman et al. on lung metas-
ases exclusively from renal-cell carcinoma. Sixty-three out
f 82 lesions were pulmonary metastases and most common
otal dose was 40 Gy in 4 fractions. They obtained a local con-
rol rate of 98% and a median survival of 32 months with follow-up time of 52 months (range 11–66). The authors
ustified these excellent results in relation to different biol-
gy of renal cell carcinoma; in which induction of immune





could play an important role.25 Milano et al. reviewed data
collected prospectively from 293 metastatic lesions in 121
patients. Most of the primary tumors were breast or colorec-
tal cancer. One hundred and three out of 293 lesions (35%)
were pulmonary metastases, with median gross tumor vol-
ume  (GTV) of 3.7 mm (range 0.08–101.8). Median prescribed
dose was 50 Gy in 10 fractions. The 2-year and 4-year tumor LC
rates were 77% and 73% respectively. Larger GTV, liver lesions
and metastases from primary gastro-intestinal cancer were
correlated to poor disease control. On the other hand, breast
cancer patients had better survival and local control rate.26,27
Other experiences confirmed the same data about survival and
prognostic factors.28–31
4.2.2.  SBRT  for  only  lung  metastases
Norihisa et al. treated 34 patients for 43 lesions with maximum
diameter of 4 cm.  The primary site of disease was controlled
and there were no other organs involved. The total dose of
48 Gy in four fractions was escalated to 60 Gy in five fractions
for 16 patients, with median overall treatment time of 12 days.
The majority of the lesions had a tumor diameter less than
3 cm (91%). After a median follow-up time of 27 months (range
10–80 months), they observed the 2-year overall survival (OS),
local control (LC) and progression-free survival (PFS) of 84.3%,
90% and 34.8% respectively. No significant differences were
found between two different dose levels. Survival difference
was significant and only related to disease-free interval (DFI),
with greater OS in a subgroup with DFI more  than 3 years.32 A
similar experience was reported by Rusthoven and colleagues.
They enrolled 38 patients with one to three lung metastases,
most of them from colorectal cancer. The total dose was safely
escalated from 48 to 60 Gy. Median GTV was 4.2 mL (range
0.2–52.3). The 2-year LC and OS were 96% and 39% respectively,
with median follow-up time of 15.4 months (range 6–48). This
poor OS rate could be explained because the majority (82%) of
treated patients had one or more  unfavorable prognostic fea-
tures as 3 thoracic lesions, extra-thoracic disease, disease-free
interval less than 36 months, or 2 prior chemotherapy regi-
mens for metastatic disease.9 Also Oh et al. published their
results on 57 patients with lung oligometastases (a total of
450  reports of practical oncology and radiotherapy 2 0 ( 2 0 1 5 ) 446–453







Primary site Dose LC Toxicity







G3  (pneumonitis) in
5 pts






G5 (lung) 3.3% (one
pt)
Milano et al. 2008/2012 121 103/293 All (mostly breast
and colorectal)
50  Gy/10 fr/over
two weeks
2–4 year LC 77%,
73%
G3 (lung) in one pt
Kang et al. 2010 59 18/78 Colorectal
carcinoma
39–51  Gy/3 fr 3-year LC 66% G1-2 (lung) in 6 pt
(46%)
Inoue et al. 2010 41 22/60 All (mostly lung) 35 Gy/4 fr 3-year LC 80% Intercostal neuralgia
in one pt





2-year LC 66.7% G3 (fatigue) in 2 pt
G3 (lung) in one pt
G3 (neurologic) in
one pt








G3  (hypoxia) in one
pt
G3 (pneumonitis) in
one pt67 lesions). Total dose was 50/60 Gy delivered in 5/4 fractions.
The 3-year LC and the 2-year OS were 94.5% and 59.7% after
median follow-up time of 21 months (range 3–107). Tumor
size (<2.5 cm in 87% of patients) was a favorable prognostic
factor while presence of extra-thoracic disease or metastases
from liver and colorectal cancer were correlated with a worse
prognosis.33 More  recently, Inoue et al. published results from
87 patients and 189 treated lesions. The most common dose
fractionation was 48 Gy/4 fractions/4 days. The 2-year OS
and LC rate were 47% and 80%, respectively. Breast cancer
patients had a better local control compared with pulmonary
metastases from intestinal cancers.34 Navarria et al. reported
data from 76 oligometastatic patients with 118 lung lesions.








Norihisa et al. 2008 34 43 All (mostly
from lung)
Rusthoven et al. 2009 38 63 All (mostly
from
colorectal)
Oh et al. 2012 57 67 All (mostly
from lung)
Inoue et al. 2013 87 189 All (mostly
from
colorectal)





Following a schedule of risk-adapted dose prescription, they
received total dose of 48 Gy in 4 fractions for peripheral lesions,
60 Gy in 8 fractions for central lesions and 60 Gy in 3 fractions
for peripheral lesions with diameter ≤ 2 cm.  All patients had
controlled primary tumor, long-term of progression disease
(longer than 6 months) and number of metastatic sites ≤5.
The 2-year LC rate and OS were 89% and 73%, respectively,
with median follow-up time of 18 months (range 6–45). In this
analysis no factors statistically affected outcome of patients.
This finding could be related to the characteristics of treated
patients; most of them had unfavorable histology (mostly GI
tumor and NSCLC), all with primary tumor controlled and
disease-free interval greater than 12 months.10
tases.
Dose LC Toxicity
48 Gy/4 fr–60 Gy/5 fr
within 4–18 days (median,
12 days)
2-year LC 90% G2 12%
G3 (pneumonitis)
3%
48–60 Gy/3 fr 2-year LC 96% G3 (pneumonitis)
2.6%
50–60 Gy/5–4 fr 3-year LC 94.5% G2 (lung) 6%
G5 in one pt
Rib fractures 13%
48 Gy/4 fr/4 days 2-year LC 80% G3-4 10%
(G4 in one pt)
60 Gy/3 fr (peripheral)/3
days
48 Gy/4 fr (peripheral >2 cm)
4 days
60 Gy/8 fr (central)/10 days
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.  Prognostic  factors
.1.  Histology
s previously described, many  authors analyzed the progno-
tic impact of primary tumor’s histology. In the Hof’s series
he local progression-free rate was lowest in metastases from
olorectal cancer (0% at 36 months) compared with other his-
ologies. Anyway, no statistically significant influence on local
umor control was found [20]. Also Oh’s group confirmed this
rend for metastatic tumors from the colorectum and the liver,
ith lower local control rates than those from other tumors
81.8%, 80.0%, and 100%, respectively, p = 0.04).33 Inoue et al.
videnced a trend toward a worse local control for metastases
rom intestinal cancer with respect to breast cancer.34 Milano
nd colleagues showed that patients with breast cancer have
uch better survival than other histologies. Progression-free
urvival at 2 years was 36% for patients with breast cancer
ompared with 13% for those with non-breast cancers, and
verall survival at 6 years was 47% vs. 9%. The rate of local
ontrol is also higher.26 Other experiences confirmed a wors-
ning in local control in patients with high-risk histologies,
s small cell lung cancer, sarcoma, renal cell carcinoma and
elanoma.23,30
.2.  Disease-free  interval
n Norihisa’s and Inoue’s series disease-free interval was asso-
iated to better OS rate. Norihisa’s group showed significantly
reater overall survival (p = 0.02) for patients with disease-
ree interval (DFI) >3 years than patients with DFI <1 year
r between 1 and 3 years.32 Inoue and colleagues separated
he patients into two groups according to interval to recur-
ence of <12 or ≥12 months. The 3- and 5-year OS rates
ere 19% and 10%, respectively, for those with an interval
o recurrence of <12 months, compared with 53% and 40%,
espectively, for those with an interval to recurrence of ≥12
onths (p = 0.006).29
.3.  Number  of  metastases
ifferent series confirmed the prognostic role of this feature.
alama’s group showed the 2-year OS was 60.3% for patients
ith 1–3 metastases compared with 21.9% for patients with
–5 metastases.30 Wersall and colleagues reported the over-
ll survival closely associated with the number of metastases.
he patients with one to three metastases had median sur-
ival of 37 months, compared with 19 months in patients
ith more  than three metastases.24 In Hof’s series the overall
urvival was significantly improved for patients with solitary
etastases not developing further metastases during follow-
p.20 Ricardi et al. showed an evident trend toward improved
FS related to the number of metastatic lesions but this data
ere not correlated at multivariate analysis. Nevertheless,he selected group of patients (n = 24) with small (<3.3 cc) sin-
le metastasis had the more  favorable outcome in terms of
rogression-free survival, with a PFS rate of 70% at 1 year and
f 52.8% at 2 and 3 years.21therapy 2 0 ( 2 0 1 5 ) 446–453 451
5.4.  Size  of  metastases
The influence of tumor volume on local control is still an out-
standing issue. However, most of the studies’ data confirmed
a close association between smaller lesions and improve-
ment of local control rate. In several series smaller tumor
volume was correlated to better disease control.20,24,31 Sim-
ilar data were described in univariate analysis by Osti et al.
with a significant correlation between tumor small volume
(<10 cc) and LC probability (p < 024).23 Milano’s and Kang’s
group showed tumor volume as independent prognostic fac-
tors of overall survival26,28 but in these series the majority of
the treated lesions were not pulmonary metastases (only 29%
lung lesions, considering both studies). On the other hand,
Oh and colleagues reported more  favorable survival (64.0% vs.
38.9% at two years, p = 0.032) for patients with tumors smaller
than 2.5 cm only at univariate analysis.33 Moreover, tumor
volume was significantly correlated to OS, CSS and PFS on
multivariate analysis in Ricardi’s series.21
5.5.  Other  prognostic  features
Other characteristics of patients’ population could influence
survival and disease control rate. In Oh’s univariate analysis
patients with extrathoracic disease had lower survival (66.1%
vs. 0% at two years, p = 0.003); multivariate analysis showed
that the presence of extrathoracic disease was the only sta-
tistically significant factor (p = 0.049).33 A similar result was
reported by Inoue’s group for ECOG performance scale (PS) that
was significant by both uni- and multivariate analyses.34
6.  Assessment  of  treatment  response
Radiation-induced CT lung changes after SABR differ from
those observed after conventionally fractionated radiotherapy.
SABR employs complex beam arrangements to conform high-
dose regions to the tumor and create steep dose gradients
around the target volume, with a relatively large volume of
lung receiving low/intermediate doses. Radiologic aspect after
SBRT can be difficult to analyze and RECIST criteria could be
inappropriate.35 In some instances, CT changes after SABR can
develop as mass-like patterns that mimic  the appearance of
recurrent disease. Benign CT lung changes follow common
acute and late patterns, appearing predominantly as con-
solidation within the first 6 months after treatment, with a
modified conventional pattern of fibrosis emerging 6 months
to years after treatment. Current follow-up relies mainly on
CT imaging, with positron emission tomography (PET) or
biopsy when recurrence is strongly suspected. An enlarging
CT opacity after SABR is the most frequently reported fea-
ture of recurrence. Although PET SUVmax may transiently
rise immediately post-SABR and persist for over 12 months
without recurrence, SUVmax ≥ 5 may serve as a useful cut-
off for recurrence. The available evidence currently supports
a definition of a recurrence as meeting either of two  criteria:
(1) increase in tumor size on CT imaging with SUVmax ≥ 5,
or (2) pathology-proven disease.36 Promising new techniques
may involve more  robust analysis of currently-obtained imag-
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imaging modalities into routine clinical practice. Additional
PET tracers such as 18-fluoroazomycin-arabinoside (FAZA) and
18F-fluoromisonidazole (F-MISO) are used for imaging hypoxia
and perfusion imaging (CT or MRI-based) and have shown
promise as prognostic or predictive biomarkers in oncology.
All of these new imaging modalities could also be investigated
for assessing response following SBRT.37
7.  Combined  SBRT  and  systemic  therapy
The big question in this group patients is if, how and
when to integrate SBRT with systemic therapy. The issue is
ongoing and to date no clear evidences are available. Few
studies were published on concomitant chemotherapy or
biological therapy and fractionated or moderate hypofrac-
tionated radiotherapy.38 Again, no selected studies about
oligometastatic patients have been published. The only data
employed concern patients with limited metastatic disease at
diagnosis using a single drug or platinum-based chemother-
apy given concurrently with radiotherapy.39,40 Therefore,
further evidences are needed.
8.  Patients  selection  and  future  perspective
Many  non-randomized studies have shown that SBRT for
oligometastases is safe and effective with local control rate
of about 80%. In most of the cases toxicity seems to be mod-
erate and acceptable. The impact on survival outcomes is
still unclear and prospective randomized trials are needed
to confirm this issue. Recently, different cooperative groups
are outlining prognostic model using age, tumor diameter,
Performance Status and BED, to define the benefit of SBRT
in terms of overall survival in patients with early-stage lung
cancer.41 Several prognostic factors regarding patients (age,
KPS, comorbidity), disease status (histology, disease-free inter-
val time, control of primary tumor, other metastatic sites)
and characteristics of SBRT in relation to site and size of
lung metastases, total dose delivered, fractionation and treat-
ment time period have been investigated in oligometastatic
patients and detailed in previous section. Based on pub-
lished studies, the patient that might have major benefit from
SBRT is patient with: breast histology, disease-free interval
≥12 months, control of the primary tumor, small lesions,
limited number of lesions (up to three) and higher radiation
dose delivered (BED > 100 Gy). Well-designed collaborative tri-
als, including not only stratification of patients by histology
but also considering disease-free interval, number and size of
metastases, are necessary to draw final conclusions. To date,
the discussion within a multidisciplinary team becomes cru-
cial to perform a careful patients’ selection in the setting of
oligometastatic disease.Conflict  of  interest
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